Pharmaceuticals, Biotechnology and Life Sciences
The U.S. Food and Drug Administration (FDA) has said that it plans to take a better look on how drug-makers describe their products and to make them focus on better explaining what the drug exactly do, and how consumers and healthcare professionals (HCPs) can detect false promotions.
Celyad has started on Thursday its Therapeutic Immunotherapy with NKR-2 (THINK) trial in Belgium with the first patient giving blood.
To remind, THINK trial is an open-label Phase Ib study to assess the safety and clinical activity of multiple administrations of autologous CAR-T NKR-2 cells in seven refractory cancers.
Valneva has given Merck in United States and Canada rights to use its EB66 technology to research new veterinary vaccines.
OptiBiotix Health is rearranging its directorial staff as it has changed its Commercial Director. Namely, Jim Laird will be substituted by Per Rehné to that directorial position.
Nicox has provided certain regulatory and clinical updates for NCX 4251, its novel ophthalmic suspension of fluticasone propionate nanocrystals being…
Neovacs and Professor Robert Kerbel and his team at the Sunnybrook Research Institute of Toronto, Canada are about to join…
Bayer has started off the new year with another approval from theU.S. Food and Drug Administration (FDA).
Sanofi’s Soliqua 100/33 (insulin glargine 100 Units/mL & lixisenatide* 33 mcg/mL injection) is now available by prescription in U.S. pharmacies.
J&J’s DePuy Synthes Products, Inc. has bought asset and signed development agreement with Interventional Spine, Inc., a privately held manufacturer…
Eli Lilly’s subsidiary Elanco US has completed the acquisition of Boehringer Ingelheim Vetmedica, Inc’s (BIVI) U.S. feline, canine and rabies vaccines…